The expansion will include the addition of two floors to its existing suite and installation of additional equipment on the current floor. The new facilities are slated to begin operations in 2022.

The investment in the expansion is part of the contract development and manufacturing organization (CDMO)'s plan to grow cell and gene therapy (CGT) capabilities around the world, according to AGC.

This announcement follows AGC's acquisition and integration of the MolMed facilities in Italy less than one year ago. The Milan site was the first good manufacturing practice (GMP) facility approved in Europe for ex vivo gene therapy manufacturing and has experience with two commercial CGT products.

With this, AGC is one of the only CDMOs offering plasmid production and end-to-end CGT services.

AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...

AGC Biologics, Molecular Partners develop COVID-19 protein therapy
AGC Biologics has partnered with clinical-stage biotechnology company Molecular Partners to create a protein therapy against SARS-CoV-2, the virus that...

AGC Biologics expands plasmid manufacturing capacity
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of...

AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.